Targeting of anti-tumor responses with bispecific antibodies.
T cells can be induced to specifically lyse tumor cells with bispecific antibodies containing anti-T cell receptor mAbs crosslinked to anti-tumor mAbs. Such "targeted cytolysis" requires that the target cell be bound directly to the cytotoxic cell. In addition, targeted T cells mediate a second activity, the secretion of factors that can block the growth of both tumor target cells and bystander tumor cells. When given to nude mice bearing intraperitoneal human ovarian carcinoma, targeted human T cells cause the rapid removal of most tumor cells from the peritoneum, and markedly prolong the times of survival of treated mice. The efficacy of targeted T cells for treating human cancer is currently being tested in clinical trials.
Segal
D M
DM
Experimental Immunology Branch, National Institutes of Health, Bethesda, MD 20892.
Qian
J H
JH
Mezzanzanica
D
D
Garrido
M A
MA
Titus
J A
JA
Andrew
S M
SM
George
A J
AJ
Jost
C R
CR
Perez
P
P
Wunderlich
J R
JR
D000818:Animals; D000970:Antineoplastic Agents / Q000276:immunology*; D003602:Cytotoxicity, Immunologic; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods; D013601:T-Lymphocytes / Q000276:immunology*
D000970:Antineoplastic Agents